Provention Bio Inc. (NASDAQ:PRVB) reported Q2 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $746 thousand versus the consensus estimate of $696.67 thousand.
Provention Bio Inc. (NASDAQ:PRVB) reported Q2 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $746 thousand versus the consensus estimate of $696.67 thousand.